Tagged with R

Bayer BV Netherlands As much as this report is about business trends and insights, we also like to portray the personalities of the industry in the markets that we cover. What has been your professional trajectory that led you to the head of Bayer Schering Pharma here in the Netherlands? I am originally…

Novo Nordisk UK This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does the European region and the UK represent for the company? The European markets are growing in the order of 3-5%…

Almirall UK The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall was founded in 1943 in Barcelona (Spain) and in 1944 it started its industrial and commercial activity. In the 60s…

Merck Sharp & Dohme Limited (MSD) You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the UK operations? As General Manager of the Merck/Schering-Plough Joint Venture in the US, I was responsible for the commercial operations…

Shire International Licensing BV Netherlands Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these four continents. What is the strategic role that Shire Netherlands plays and how does this role fit into the group’s…

Herbal Science Herbal Science started in 1985 as team of two pharmacists and now represents a large 200-person operation. What have been the main challenges for the company in this transformation and what is it most proud of? Obviously getting new business and maintaining our existing relationships has been very important for…

Association of the British Pharmaceutical Industry (ABPI) Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last year. How did the latest revision contribute to taking the research-based industry forward and what has been the impact of…

Office for the Strategic Coordination of Health Research (OSCHR) It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some examples of the new way forward. According to you, what are the factors that drove Government to pursue such drastic…

Pfizer UK As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to build greater trust on both sides in order to improve the uptake of new products and foster innovation in the…

British Generic Manufacturers Association (BGMA) Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic medicines, can you please explain the success of generic medicines in the UK? The important aspect about the UK, which…

Association of the British Pharmaceutical Industry (ABPI) What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the recent history of the pharmaceutical industry in the UK, perhaps one of the areas that we have been most successful…

AstraZeneca UK AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been performing in its home market and what will be driving your growth in the UK? Our financial results are in…